Lynx1 Capital Management LP, 10% Owner at TScan Therapeutics, Inc. (TCRX), bought 1,200,000 shares at $1.20 ($1.4M) on 2025-05-20, disclosed to the SEC on 2025-05-21.
Open-market purchase of $1.4M TCRX by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| KRRO | BUY | 2026-04-02 | $6K | — | Filing → |
| TCRX | BUY | 2025-12-23 | $218K | — | Filing → |
| NEUP | BUY | 2025-10-23 | $6.6M | — | Filing → |